Vendor Selection and Bridging Strategy

How Upstream Vendor Decisions Shape Downstream Clinical, Regulatory, and Commercial Outcomes

 

Executive Summary

In combination product development, the selection of a device constituent vendor is among the most consequential upstream decisions a sponsor will make. We examine how regulatory authorities expect to review combination product data when the device constituent is vendor supplied and the downstream impact this procurement decision has across the entire program. Vendor alliances become regulatory and development architecture decisions that determine clinical strategy, evidentiary burden, lifecycle flexibility, and ultimately, asset valuation. Unfortunately, vendor decisions are routinely made too early, too narrowly informed, and with too little appreciation for the downstream regulatory and clinical consequences. The result is predictable: sponsors discover at Phase 3 that their device vendor selection has constrained their bridging options, inflated their clinical burden, or created development and inspection vulnerabilities that threaten the program timeline.

The central thesis is straightforward: the device vendor you select today is the co-author of your regulatory and commercial future. Choose poorly, and you will spend years and significant capital correcting the decision.

 

Vendor Selection as Clinical Strategy

 

The Bridging Equation

Vendor capability can narrow the bridging strategies available to a sponsor. The upstream vendor selection decision may, despite the best intentions, increase clinical cost and have rippling downstream consequences. Further, lacking finality in vendor selection often has equally devastating consequences. The later the platform or vendor switch, the greater the initial capabilities gap identified or gap being bridged, the more complex the bridging pathway, the more substantial the time and financial investment required to complete. Consider these two illustrative composites, both encountering the same hurdle, but able to pull different levers to progress.

Case Archetype: The Late Discovery

A sponsor selects a commercially available autoinjector platform from a well-known vendor for clinical supply. The device has been used with multiple other legally marketed programs and has a widely used Drug Master File (DMF). These factors paint the delivery system as a low-risk choice. Phase 1 and Phase 2 proceed without device-related issues. While planning the Phase 3 program, the sponsor discovers three compounding problems. First, the vendor’s capabilities, designs, and DMF only supports a 1.0 mL fill volume, but Phase 2 data indicate the optimality of a commercial 1.5 mL single-injection dose. Second, the vendor’s summative human factors study was conducted with a population that does not include the sponsor’s target patient demographic. Third, and most critically, the sponsor does not have design verification and validation data needed to support an engineering comparability argument because the vendor didn’t previously test a 1.5 mL fill volume.

The result: the variances identified change the device’s intended use and dose delivery characteristics and require significant new data to support the system’s safety and efficacy. Further, the sponsor does not have the design verification and validation data needed to collaborate and refine an engineering comparability argument, limiting the sponsor’s bridging flexibility. Ultimately, the sponsor is cornered and undertakes new pharmacokinetic bridging, dedicated human factors validation, and expanded sponsor-owned engineering comparability studies. The program is delayed 14–18 months, costs balloon by $8–12M, and a major programmatic pivot must be executed before the pivotal trial can begin. The root cause is not a device failure, but the result of selecting a vendor without sufficient transparency and total program buy-in.

Case Archetype: The Proactive Alignment

A sponsor engages a device vendor early in Phase 1 planning. The vendor’s autoinjector platform has three prior combination product approvals, an established EDDO evidence package with documented statistical confidence intervals, a summative HF study covering multiple patient populations, and the vendor is willing to execute a quality agreement that provides the sponsor with review rights to the vendor’s design verification and validation data and Master File.

At Phase 3, the sponsor again faces the same dosing and usability dilemma, but with the greater data insight, is able to execute a streamlined bridging strategy. Bench verification confirms where EDDO comparability can be leveraged from the prior configuration. The human factors data are supplemented with a targeted summative study for the specific patient population and intended use. Existing bioavailability data supplement the presented bench testing to support a bioequivalence determination. While the device-related clinical and regulatory workstream adds approximately 8 months and $2–3M to the program, planning and data sharing effectively managed the cost and timeline impacts.

In both these cases, the sponsor began with the best intentions and worked to plan to meet their long-term goals. Where the archetypes diverge is when a foreseeable obstacle is encountered: In the former, the sponsor is blinded to the vendor’s data and clinical and bridging programs are derailed; in the latter, the sponsor is able to learn from the data package and the vendor becomes an active ally in driving toward bridging success.

Why Vendor Selection is a Regulatory Decision

 

The Combination Product Framework

The combination product primary mode of action determines the regulatory pathway, review standards, and applicable quality system requirements. Manufacturers and developers must navigate layered compliance obligations spanning safety, efficacy, and bridging. These all flow directly to the device vendor. All vendors have their limitations, complicating matters. Practically, while the path to combination product approval is paved with options, the device constituent’s regulatory posture and capabilities narrow the available path across the entire development cycle. Sponsors that defer vendor selection to their supply chain team, rather than as a layered regulatory and development architecture decision, undermine the available scope and evidence package possible to support approval.

Global Alignment

The sponsor’s intended geographic footprint should inform vendor selection at program genesis. The regulatory framework for combination products varies by jurisdiction and the vendor’s ability to support multi-regional submissions is critical. The first step is to understand FDA’s requirements for combination products and clinical bridging, some of the most stringent globally. Effectively integrating risk management, usability engineering, and performance data throughout development, with quality oversight, produces not merely a US evidence package, but a technical foundation for global submissions. Sponsors and vendors who execute US combination product development with rigor and operational alignment position themselves for global success.

Significant global overlaps persist, but bridging strategies should not only be tied to US submissions. Early accounting of regional nuance and working with vendors who can support the level of planned global deployment set the program on the path to success. EU MDR, ISO 14971, IEC 62366, and GSPR performance requirements overlap significantly with FDA’s EDDO expectations and methodologies for evidencing the device portions of clinical bridging. So, while robust FDA-level documentation reduces duplication, facilitates technical file creation, and accelerates market expansion, a vendor whose documentation is tailored only to a single jurisdiction creates incremental work and adds risk at every subsequent market entry. Vendors without an EU MDR compliance pathway (i.e., no conformity assessment history, no Technical File or Design Dossier available to support Competent Authority review) create a structural gap in the sponsor’s global submission strategy that US approval cannot bridge in isolation.

The same principle extends beyond Europe: Health Canada, Australia’s TGA, Japan’s PMDA, and the UK’s MHRA each impose device constituent expectations that reward early technical depth and compliance assurance. A vendor selected and qualified to the standard required for US approval is substantially more likely to satisfy those expectations without requiring a parallel device development program, but the converse is equally true. A vendor selected without global compliance infrastructure can force re-qualification precisely when supply chain stability matters most: global expansion.

The QMSR Transition and Its Impact on Vendor Selection and Bridging

The recent implementation of FDA’s Quality Management System Regulation (QMSR), incorporating ISO 13485: 2016 into 21 CFR Part 820, represents a significant shift in vendor qualification expectations. Further, recent compliance activity shows sponsors must evaluate their internal and supply chain’s quality system framework, particularly regarding the explicit integration of risk management and the documentation requirements for design and development planning. The QMSR integration grants FDA greater inspectional authority over internal records and, effectively, broader visibility into the total dataset used to determine supply chain adequacy. This means that a device vendor’s quality system can be more effectively audited in the context of the sponsor and the specific combination product(s) marketed and developed. Vendors who have not adopted QMSR represent a compliance liability that sponsors are obligated to identify and manage through supplier qualification. Unresolved non-compliance adds program risk and diminishes long-term supply chain viability. Because early strategic decisions hinge on vendor capability, QMSR compliance should be an explicit requirement in vendor qualification, confirmed before platform selections are made and discovered before long-term engagements are executed.

What Regulators Expect to See

When reviewing a combination product’s bridging methodology and data, regulatory authorities are assessing a defined set of questions. The complication, when using a vendor-supplied device constituent, is information access when creating a cohesive and comprehensive regulatory package. Setting clear and reliable information channels early during development positions sponsors to clearly answer regulator inquiries and hedge against review delays. Anticipating the reviewer’s lens ensures that the filing addresses the critical regulatory assessment points head-on:

• Does the sponsor understand how the device affects safety and effectiveness of the drug or biologic? This is the threshold question. If the submission does not clearly articulate the device’s role in drug delivery and its impact on clinical outcomes, the reviewer has no basis for confidence in the overall product.
• Are drug delivery specifications / Essential Drug Delivery Outputs (EDDOs) clearly defined, measurable, and verified? The core drug delivery requirements (in US: EDDOs, formerly Essential Performance Requirements) must be tied to labeling claims, supported by objective verification methods, and demonstrated under worst-case conditions including aging.
• Do any device changes necessitate additional clinical data? The modification history of the device, and the sponsor’s characterization of those modifications relative to EDDOs, determines whether bench data suffices or clinical bridging is required.
• Are design controls and change management robust under ISO 13485: 2016 / 21 CFR Part 820 (QMSR) + 21 CFR Part 4? The reviewer will evaluate whether the vendor’s quality system demonstrates adequate control over the device constituent, including traceability, CAPA effectiveness, and change control governance.
• Are labeling claims supported by validated performance? Every claim in the labeling must be traceable to verified EDDO performance data.
• Is bridging scientifically justified and statistically supported? The bridging rationale must address both dose delivery accuracy and clinical effectiveness, with appropriate statistical confidence.
• Is dose delivery efficacy as well as clinical effectiveness clearly addressed in the bridging protocol and report? This is a frequent deficiency: sponsors must address device performance but fail to close the loop to clinical outcomes.

If vendor selection decisions compromise any of these elements, regulatory risk increases significantly. Unfortunately, the latent risk may not become apparent until contracts are executed. The key is asking informed questions early and establishing confidence that the vendor will engage as a development partner, not just a supplier.

 

EDDOs: The Connective Tissue Between Vendors and Sponsors

Vendor selection and collaboration determine the sponsor’s ability to define EDDOs early, collect robust evidence, and maintain that evidence through an asset’s lifecycle. EDDOs act as the key throughline connecting device bridging, commercial expectations, and vendor capability discussions. Early, vendor-aligned EDDO definitions orient combination product development with regulatory expectations.

Consider FDA’s aspirational guidance to use the final finished form of the combination product across the clinical program. While often impractical for a myriad of reasons, initiating clinical trials with EDDO agreement effectively refines development objectives and helps force early clinical translation to commercial presentation with vendor input. This meets FDA’s core structural intent: to tie drug-delivery outputs to clinical outcomes. While terminology has evolved, treating EDDOs as the connective tissue between measurable device performance parameters, drug delivery, and clinical safety and effectiveness aligns the device engineering and the clinical research programs. Maintaining this alignment is contingent on proper vendor selection and has a direct impact on the final bridging strategy.

EDDO Definition and Vendor Capability

For each device function impacting drug delivery, the sponsor must define an EDDO that is measurable, clinically relevant, and linked to risk analysis. Typical EDDO categories for injectable delivery systems include delivered dose accuracy, dose volume, injection time, activation force, needle penetration depth, and lockout functionality. The vendor’s role is critical at each step:

• Definition: Can the vendor provide historical tolerance data and manufacturing capability indices to inform clinically justified acceptance criteria?
• Verification: Does the vendor have validated test methods, adequate sample size justification approaches, and statistical confidence in their performance data?
• Validation integration: Can the vendor support human factors validation? Are there data which confirm real-world users can operate the system with EDDO specifications? Is the usability engineering file complete or the pathway to completion clear?
• Lifecycle monitoring: Does the vendor have post-market complaint trending, drift monitoring, and stability re-confirmation programs that maintain EDDO performance over the product lifecycle? How willing is the vendor to collaborate on submissions to maintain system safety and efficacy?

At Suttons Creek, we work with our clients to scope EDDOs for long-term product viability and in consideration of any vendor constraints. Our EDDO and bridging strategic assessments are part of our broader practice to align vendor selection, regulatory architecture, and bridging strategy. Engaging at the earliest effective stage of combination product development allows strategic direction to be set before commitments harden into constraints.

EDDOs Create Value Beyond Compliance

Sponsors who treat EDDOs solely as a compliance obligation miss a significant strategic opportunity. Well-defined, rigorously evidenced EDDOs can support differentiating labeling claims, premium positioning, refining data strategy, and promoting a superior adherence narrative. Examples include tighter dose accuracy than competitors, reduced injection force, and lower variability across temperature ranges in addition to cost-efficient process-related effects such as reducing defects and increasing first-pass yield. Realizing this value requires a vendor who can support robust statistical evidence, allow design iteration, and effectively partner during development and scale-up. Vendors with restrictive IP terms or limited data transparency prevent sponsors from leveraging EDDOs as competitive assets.

As teams move through device development, movement from planning to execution will inevitably reveal technical obstacles. Sponsors who proceed with collaborative vendors will face these challenges with diverse solutions solicited from the team to drive forward faster and more effectively. Nowhere is this more evident than when proceeding into the engineering foundation for all device-related bridging arguments: Design Verification and Validation (DV&V).

 

Design Verification, Validation, And Labeling

 

Verification: Where Vendor Quality Shows

Vendor quality directly impacts the verification program in several dimensions. Traceability matrix quality depends on the vendor design documentation clearly linking to EDDOs. Risk management integration and totality per ISO 14971: 2019 depends on vendor and sponsor data transparency, system reliability, dose uniformity, data integrity, and sub-tier supplier controls.

FDA expects verification of all EDDOs under a variety of labeling-defined, reasonably conceivable conditions. Drug-device compatibility data are expected to include extractables/leachables, container closure integrity, system biocompatibility, and any materials of construction specific considerations. Environmental and shipping validations are also influenced by EDDOs. A weak vendor results in gaps in verification, inadequate statistical justification, inspection risk, and late-stage data gaps that trigger deficiency questions. At Suttons Creek, we assist our clients by performing vendor due diligence assessments to identify strategic vulnerabilities, resolve vendor gaps, fortify the sponsor’s bridging position, and allay late-stage bridging or review surprises.

Validation: The Clinical Bridge

Design validation is the cornerstone of clinical bridging because it answers the essential delivery question: is the dose effective? Design validation is the device constituent’s guiding principle across clinical bridging. The device’s design validation data touches practically all elements of the bridging program, including evidencing usability, dose delivery efficacy, and clinical efficacy correlation.

Using human factors validation as a case study, clarity on formative and summative human factors testing, overlap with the intended user population, confidence in the use-related risk analysis and identification of critical tasks all influence the bridging strategy and partially depend on the vendor’s willingness to support the sponsor. Use questions are amplified as the sponsor explores home-use, pediatric, geriatric, and other special considerations demanded by the indications for use. If the vendor’s existing human factors data do not cover the sponsor’s intended patient population, use environment, or device configuration, a new program is required regardless of the device’s prior regulatory history. Additionally, questions surrounding ‘production equivalence’ may arise and ensuring that design validation units are truly representative become critical. Early acknowledgement and honesty of this reality addresses one of the most common sources of avoidable development delays in combination product programs.

Vendor philosophy directly affects data access. Without a sound shared data narrative and strategy, the usability engineering file may become divergent, changes may be poorly documented and evidenced, and the bridging methodology may deteriorate. A clinical bridge, be it to clinic, home, or future open-label extensions, requires reliable and unambiguous data and a reliable vendor-partner.

Labeling Implications

Vendor selection and the collectively developed data directly constrain the sponsor’s labeling flexibility. The device description section, delivery instructions for use, in-use warnings and precautions, environmental limitations, and patient population claims are all shaped by the vendor’s design, data, and intellectual property terms.

Vendor control over critical intellectual property may reduce clinical bridging leeway and future indications expansions, claim modifications, use condition optimization, or even throttle access to key supporting data needed during regulatory review. This is a structural limitation that is difficult to renegotiate once a program is in late-stage development or review.

 

Market Dynamics: The Landscape Shaping Vendor Decisions

The device vendor landscape, particularly for wearables and injectables, is undergoing significant structural changes. Sponsors must account for these dynamics when making selection decisions and ensure the long-term viability of the relationship.

Biosimilars face a combination product demand wave: The current wave of biosimilar development, particularly for subcutaneous monoclonal antibodies and other injectable biologics, has dramatically increased demand for qualified delivery platforms. Vendors with established regulatory histories are expanding capacity to preserve platform access, customization flexibility, and clinical supply capacity. Further, as these pressures balloon costs, biosimilar sponsors face a structural strategic fork. Aligning with the reference product’s device type reduces comparative-use human factors burdens and lowers interchangeability barriers but constrains platform choice and limits device differentiation as a commercial driver. Selecting a meaningfully different device enables branding and user experience differentiation but increases bridging requirements, and costs, in an environment with thin margins. In practice, most sponsors seek to land between these extremes, requiring early regulatory engagement to determine whether device differences from the reference product are major or minor, and vendors can play a supporting role by informing sponsors of valuable platform configurations, existing regulatory documentation, and customization boundaries.

Product and portfolio platforming: Many sponsors are drawn to reduced innovation and expansion costs to select an established platform for a product, portfolio, or their entire catalogue of medications. However, terms of these arrangements may restrict design modification, limit data access, and impose change control obligations that reduce sponsor flexibility. Quality, supply, and development agreements are all on the table and play a role in effective partnership definition. Sponsors should not assume vendors will proactively surface these terms; each agreement type carries direct implications for bridging strategy, lifecycle management, and indication expansion.

Home use and the user experience: Greater regulatory scrutiny and consumer demands have forced delivery platforms to become more user focused. Particularly, the notion that one-size-fits-all fails as we stratify patient populations and consider chronic use-cases. This may raise awkward late-stage questions to the device vendor if these constraints are poorly investigated early or post-market experience necessitates a design iteration.

Digital integration and connectivity: Regulatory expectations for connected devices and digital health integration are evolving rapidly. Sponsors considering platform vendors must evaluate not only current mechanical performance but also the platform’s architecture for digital connectivity, adherence monitoring, and data integration. These are capabilities that will increasingly influence regulatory review, payer acceptance, and competitive positioning.

Given the evolving landscape, and recognizing that trade-offs are frequently necessary, sponsors should use a structured framework when assessing vendor selection. These decisions correlate to downstream regulatory, clinical, and commercial success and warrant devoting commensurate scrutiny, capital, process, and time to safeguard long-term asset value. Sponsors should evaluate prospective vendors against costs, organizational stability, anticipated regulatory pathway, clinical burden, EDDO/V&V robustness, human factors program definition, quality maturity, change controls, and lifecycle flexibility and identify clusters of moderate or high risk that may compound. Vendors scoring moderate across four or five domains may represent greater aggregate risk than a vendor scoring high in a single domain, presenting greater future program risk.

Asset Valuation and Competitive Positioning

While the pharmaceutical delivers the desired therapeutic outcome, the device constituent is a direct driver of patient experience, adherence, real-world outcomes, payer acceptance, and competitive differentiation. This reality ties the vendor and their delivery system to commercial acceptance. A commodity device competes on drug alone and offers minimal differentiation. A purpose-built, optimized device enhances total asset value, enables premium pricing, and supports lifecycle extensions.

In an increasingly competitive landscape, the device constituent can become the primary differentiator visible to patients and prescribers. There have been instances where the first to market stumbled due to deficient delivery platform and vendor selection decisions. Sponsors should weigh cost savings against strategic value constraints and iteratively position the program at each critical juncture of the clinical bridging program to maintain a future competitive edge on patient experience and adherence, which are increasingly central to payer and market access decisions.

 

Conclusion

Vendor selection for the device constituent of a combination product is not a procurement decision. It is a regulatory architecture decision that locks in clinical strategy, determines evidentiary burden, defines lifecycle flexibility, shapes inspection risk, and influences asset valuation.

The sponsors who navigate this decision most effectively are those who engage regulatory, clinical, device engineering, quality, and commercial functions at the point of vendor selection. These technical areas bear the long-term relationship burden, the responsibility for ensuring bridging success, and accountability for total program execution. The most successful sponsors use the bridging paradigm to evaluate vendors not only on current capability but on the downstream program implications for development, lifecycle management, and global market access. A defined structural foundation for supply-chain relationships informs clinical efficiency, lifecycle agility, global harmonization, investor confidence, and long-term asset value maximization.

In combination products, the device vendor is effectively a co-author of your regulatory future. The decisions you make upstream define the options you have downstream.

Your Next Steps in Vendor Readiness

Take the below complimentary online assessment to better understand your program’s vendor posture and bridging readiness.

At Suttons Creek, we work with pharma, biotech, and device sponsors to align vendor selection with clinical and regulatory strategy from the earliest stages of combination product development. Our team brings direct experience in global combination product submissions, bridging strategy design, drug-delivery specification framework development, device vendor due diligence, and regulatory alignment to position tomorrow’s innovations for success today.

If your organization is evaluating device vendors, designing a bridging strategy, or navigating a regulatory interaction involving a vendor-supplied device constituent, we can help you identify and mitigate the upstream decisions that determine downstream success. Common engagement entry points include:

• Pre-IND vendor selection to conduct due diligence on regulatory posture, data access terms, EDDO evidence maturity, and QMSR compliance status, before platform commitments are made
• Phase 3 device lock readiness to review the bridging strategy and confirm the clinical configuration’s connection to the commercial form with the available data
• Mid-program vendor changes to evaluate data gaps, analyze data implications, and prioritize remediation activities
• Regulatory meeting interaction support involving device constituent characterization or EDDO specification topics.

 Let’s start with a no-obligation, 5-minute quiz to see where you stand…